top of page

Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch

ORLANDO, FL / ACCESSWIRE / October 12, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products, today announced that it has signed an exclusive manufacturing agreement with San Diego-based Diomics for its Diocheck™ technology, a simple way for individuals to monitor for the presence of antibodies to SARS-CoV-2 (COVID-19) over an extended period of time.

The goal of the Diocheck patch is to monitor the critical gap between when a person receives a COVID-19 vaccine and when a protective level of antibodies is circulating in the body, which current reports suggest could take several weeks. It could also signal when the antibodies stimulated by a vaccine have declined and the person needs a booster.

‘This exclusive contract with Diomics to manufacture Diocheck™ allows Nutriband and our contract manufacturing subsidiary, Pocono Pharma, to showcase our capabilities with innovative new patch technologies," said Gareth Sheridan, CEO of Nutriband.

Based on Diomics' proprietary usage of an FDA-approved material, Diomat™ bioresorbable polymer, Diocheck detects and reports within 24 to 36 hours whether a person has developed a circulating level of COVID-19 specific antibodies. A positive response causes a change in skin color that is visible through the Diocheck skin patch, which resembles a nicotine patch and is expected to be effective for up to 14 days. Diomics has applied to the FDA for approval of the Diocheck™ device.

The Diocheck™ Transdermal Test is intended to be used only as an aid in monitoring SARS-CoV-2 infections or vaccine efficacy. The user places the patch on the inside of either forearm for 24 hours, and then removes the patch and monitors that area of the skin for the next 24-36 hours. If the user has not been vaccinated and has a positive response in the form of a small induration and/or erythema on the skin, they are directed to contact a medical professional for additional testing to confirm a potential SARS-CoV-2 infection. If the user has been vaccinated and does not have a positive response in the form of a small induration and/or erythema on the skin, the user is directed to contact a medical professional for additional testing to confirm efficacy of their vaccine.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA ® technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.

The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:

Investor Relations

RedChip Companies

Dave Gentry

1-800-RED-CHIP (733-2447)



bottom of page